1501 (1501) Fair Value & Analysis

Healthcare · Market cap HK$6.6B

1 1501 1501 · HK

PriceHK$30.60

Fair ValueHK$37.92

Upside+23.9%

Quality66/100

Watch 1501 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$28.25 – HK$47.60

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −4.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$19.95 – HK$38.55 · fair‑value band HK$28.25 – HK$47.60 · the HK$30.60 price screens below the HK$37.92 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1501 (1501) currently trades at HK$30.60, while our model-based Fair Value estimate is HK$37.92 — implying the stock looks roughly 23.9% undervalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1501 generated revenue of HK$1.1B at a net margin of 20.5%. Revenue grew 31.5% year over year. It earns a return on equity of 12.0%. Net debt stands at HK$106M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B

Revenue growth (YoY) +31.5%

Net margin 20.5%

Return on equity 12.0%

Free cash flow HK$278M FY2025

P/E ratio 21.8

More key figures

Operating margin 23.3%

EPS (TTM) HK$0.5700

Dividend yield 0.8%

EPS growth (YoY) +31.5%

Net debt HK$106M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1501 reported revenue of HK$1.1B in FY2025 versus HK$465M in FY2021, a compound +23.1%/yr. Reported net income was HK$219M in FY2025, compounding +11.2%/yr from FY2021.

Revenue +23.1%/yr

FY21 HK$465M

FY22 HK$586M

FY23 HK$753M

FY24 HK$852M

FY25 HK$1.1B

Net income +11.2%/yr

FY21 HK$143M

FY22 HK$132M

FY23 HK$156M

FY24 HK$192M

FY25 HK$219M

Is 1501 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$422.06	$165.35	-61%
EssilorLuxottica Société anonyme ESLOF	$205.86	$114.90	-44%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$36.54	$30.66	-16%
Becton, Dickinson and Company BDX	$147.79	$124.26	-16%
Alcon Inc ALC	$65.18	$44.21	-32%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1501 (1501) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$37.92 versus a price of HK$30.60 — about +24% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1501?

Our model-based fair value for 1501 is HK$37.92 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$30.60.

What is the quality score of 1501?

1501 has a Quality Score of 66/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1501 (1501)?

1501 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1501?

The net profit margin of 1501 is about 20.5%, meaning it keeps roughly 20.5% of revenue as net income. Based on the latest reported figures.

Does 1501 pay a dividend?

1501 currently shows a dividend yield of about 0.75% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.